Article date: September 2004
By: Matitiahu Berkovitch, Orna Diav‐Citrin, Revital Greenberg, Michal Cohen, Mordechai Bulkowstein, Svetlana Shechtman, Oxana Bortnik, Judy Arnon, Asher Ornoy, in Volume 58, Issue 3, pages 298-302
Aims
The number of published studies on the use of amoxycillin/clavulanic acid during pregnancy is small and so is the number of pregnancies investigated in those studies. In this study we wished to investigate prospectively the safety of intrauterine exposure to amoxycillin/clavulanic acid in a relatively large cohort of women.
Methods
Women treated (n = 191) with amoxycillin/clavulanic acid during the first trimester of pregnancy were recruited from two teratogen information centres in Israel. Exposed women were matched for age, smoking habits and alcohol consumption with 191 controls exposed to amoxycillin only for similar medical indications.
Results
Maternal age, birth weight, gestational age at delivery, rates of live births and abortions were comparable between the two groups. Rates of major malformations in the amoxycillin/clavulanic acid group (3/158, 1.9%) did not differ significantly from controls (5/163, 3%) (P = 0.49, relative risk = 0.62, 95% confidence interval 0.15, 2.55), and were within the expected baseline risk for the general population.
Conclusion
These data suggest that exposure to amoxycillin/clavulanic acid during pregnancy is unlikely to be associated with an increased risk of malformations.
DOI: 10.1111/j.1365-2125.2004.02138.x
View this article